| Risk | Moderately High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 1.71% |
| NAV | ₹112.17 (29 Oct 2020) |
|---|---|
| Fund Started | 01 Jan 2013 |
| Fund Size | ₹1,321 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Sequent Scientific Ltd. | Healthcare | Equity | 4.0% |
| Infosys Ltd. | Technology | Equity | 3.8% |
| Federal Bank Ltd. | Financial | Term Deposits | 3.8% |
| ICICI Prudential Life Insurance Company Ltd. | Financial | Equity | 3.7% |
| ICICI Bank Ltd. | Financial | Equity | 3.5% |
| Reliance Industries Ltd. | Energy | Equity | 3.3% |
| Lupin Ltd. | Healthcare | Equity | 2.8% |
| HCL Technologies Ltd. | Technology | Equity | 2.8% |
| Ultratech Cement Ltd. | Construction | Equity | 2.8% |
| Neogen Chemicals Ltd. | Chemicals | Equity | 2.7% |
SBI Contra Direct Plan Growth is a Equity Mutual Fund Scheme launched by SBI Mutual Fund. This scheme was made available to investors on 01 Jan 2013. Rama Iyer Srinivasan is the Current Fund Manager of SBI Contra Direct Plan Growth fund.The fund currently has an Asset Under Management(AUM) of ₹1,321 Cr and the Latest NAV as of 29 Oct 2020 is ₹112.17.
The SBI Contra Direct Plan Growth is rated Moderately High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 1 year
The scheme seeks to provide the investor with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities following a contrarian investment strategy.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.